Research graph
References from Impact of advanced therapy initiation on antibiotic dependence in chronic pouchitis. Local targets link to admitted publications; unresolved targets remain external evidence.
Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies
10.1053/j.gastro.2013.07.041 · 2013 · External reference
The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the surgical management of ulcerative colitis
10.1097/dcr.0000000000002037 · 2021 · External reference
Increasing incidence of pouchitis between 1996 and 2018: a population-based Danish cohort study
10.1016/j.cgh.2022.04.015 · 2023 · External reference
Incidence, risk factors, and outcomes of pouchitis and pouch-related complications in patients with ulcerative colitis
10.1016/j.cgh.2020.06.035 · 2021 · External reference
Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients
10.1097/sla.0b013e31827d99a2 · 2013 · External reference
Pouchitis: pathophysiology and management
10.1038/s41575-024-00920-5 · 2024 · External reference
AGA clinical practice guideline on the management of pouchitis and inflammatory pouch disorders
10.1053/j.gastro.2023.10.015 · 2024 · External reference
Vedolizumab for the Treatment of Chronic Pouchitis
10.1056/nejmoa2208450 · 2023 · External reference
Adalimumab in the treatment of chronic pouchitis. A randomized double-blind, placebo-controlled trial
10.1080/00365521.2019.1569718 · 2019 · External reference
Efficacy of Vedolizumab for refractory Pouchitis of the Ileo-anal pouch: results from a multicenter US cohort
10.1093/ibd/izz030 · 2019 · External reference
Research communication: comparative effectiveness of Ustekinumab and Vedolizumab in the management of chronic pouchitis—a population-based study
10.1111/apt.70404 · 2025 · External reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
10.1136/bmj.n71 · 2021 · External reference
Outcome of biological therapies in chronic antibiotic-refractory pouchitis: a retrospective single-centre experience
10.1177/2050640619871797 · 2019 · External reference
Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis
10.1111/apt.14479 · 2018 · External reference
Efficacy and safety of ustekinumab for chronic pouchitis: a prospective open-label multicenter study
10.1016/j.cgh.2024.04.030 · 2024 · External reference
Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series
10.1097/meg.0b013e3283525a7b · 2012 · External reference
Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis
10.1046/j.1365-2036.2003.01535.x · 2003 · External reference
Effectiveness and safety of tofacitinib in patients with chronic pouchitis multirefractory to biologics
10.1016/j.dld.2023.04.028 · 2023 · External reference
Safety and efficacy of biological therapy in chronic antibiotic refractory pouchitis: a systematic review with meta-analysis
10.1097/mcg.0000000000001550 · 2021 · External reference
Treatment patterns and standardized outcome assessments among patients with inflammatory conditions of the pouch in a prospective multicenter registry
10.1093/crocol/otac030 · 2022 · External reference
Drug persistence of first- and advanced-line therapy for chronic inflammatory pouch disorders: a prospective cohort spanning sequential treatment lines
10.1016/j.dld.2025.10.028 · 2025 · External reference
A polymorphism in interleukin-1β gene is associated with the development of pouchitis in Japanese patients with ulcerative colitis
10.1159/000503283 · 2021 · External reference
